With the ever-increasing complexity, integration capabilities, and faster pace of technological development, this burdensome approach is lacking efficiency and turning into a mandatory regulatory checkmark instead of the actual evaluation of the technology's fitness for its intended use.
Computer system validation aims to guarantee that the computer system used within different cGMP processes does not have a negative impact on product quality or patient safety, and that it ensures data integrity. On the other hand, computer software assurance (CSA) intends to simplify testing by allowing companies to perform unscripted testing and use automated tools instead of traditional testing. In fact, automated testing finds more defects than testing performed by humans since it executes steps in a sequential and systematic manner, evaluating the results with 100% accuracy, leading to less documentation.
The time has come for a significant shift from CSV to CSA, focusing on preventing the introduction of defects the software development process while applying a risk-based approach to determine the suitable level of assurance effort and activities to establish confidence in the software. Furthermore, CSA supports the maintenance of a state of control throughout the software development lifecycle. This paper aims to shed light on the industry's current challenges, highlight the pressing need for CSA implementation, and present an approach to assist the pharmaceutical sector in comprehending the necessity of CSA adoption.